Table 2.
Number of events and five year recurrence free survival according to prognostic factors.
| Variable | No. of patients | No. of events | Proportion surviving to 5 years (%) | p value | |
|---|---|---|---|---|---|
| T stage | |||||
| T1mic | 120 | 4 | 97.4 | 0.681 | |
| T1a | 93 | 2 | 97.8 | ||
| T1b | 162 | 6 | 96.9 | ||
| Age | |||||
| ≤ 35 | 23 | 3 | 90.9 | 0.002 | |
| >35 | 352 | 9 | 97.7 | ||
| Grade¶ | |||||
| 1 (low) | 28 | 1 | 96.3 | 0.696 | |
| 2 | 152 | 5 | 96.6 | ||
| 3 (high) | 71 | 2 | 98.6 | ||
| ERa | |||||
| negative | 136 | 7 | 95.1 | 0.123 | |
| positive | 237 | 5 | 98.2 | ||
| PRb | |||||
| negative | 187 | 9 | 96.0 | 0.126 | |
| positive | 186 | 3 | 98.2 | ||
| HR | |||||
| ER-PR- | 122 | 7 | 94.9 | 0.069 | |
| ER+ and/or PR+ | 251 | 5 | 98.4 | ||
| HER2c | |||||
| Negative | 276 | 8 | 97.4 | 0.772 | |
| Positive | 96 | 3 | 97.9 | ||
| HR/HER2 | |||||
| HR+HER2- | 220 | 4 | 98.6 | 0.225 | |
| HR+HER2+ | 31 | 1 | 96.8 | ||
| HR-HER2+ | 65 | 2 | 98.5 | ||
| HR-HER2- | 56 | 4 | 92.6 | ||
| HR/HER2 | |||||
| HR+ and/or HER2+ | 316 | 7 | 98.4 | 0.018 | |
| HR-HER2- | 56 | 4 | 92.6 | ||
| p53d | |||||
| <10%; | 220 | 4 | 97.9 | 0.543 | |
| ≥10% | 143 | 6 | 97.1 | ||
| Ki-67d | |||||
| <10% | 275 | 6 | 98.4 | 0.148 | |
| ≥10% | 88 | 4 | 95.5 | ||
¶ Only T1a, T1b patients were analyzed using nuclear/histolgogic grade.
a,bData of hormone receptor status was available in 373 patients. ;<10%;negative, ≥10%;positive
c HER2 status was determined by immunohistochemistry and was available in 372 patients.; 0,1+,2+;negative, 3+;positive
dData of p53 and i-67 was available in 363 patients.